{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Atacicept+75+mg", "query": { "intervention": "Atacicept 75 mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 8, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T01:36:48.498Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00430495", "title": "A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Atacicept", "type": "DRUG" }, { "name": "Placebo matched to atacicept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 256, "start_date": "2006-12", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2016-02-17", "last_synced_at": "2026-09-05T01:36:48.498Z", "location_count": 1, "location_summary": "Rockland, Massachusetts", "locations": [ { "city": "Rockland", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00430495" }, { "nct_id": "NCT00624338", "title": "Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Lupus Erythematosus, Systemic" ], "interventions": [ { "name": "Atacicept 75 mg", "type": "DRUG" }, { "name": "Atacicept 150 mg", "type": "DRUG" }, { "name": "Placebo Comparator", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 461, "start_date": "2008-01", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2016-03-14", "last_synced_at": "2026-09-05T01:36:48.498Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Palo Alto, California • San Diego, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00624338" }, { "nct_id": "NCT01972568", "title": "Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lupus Erythematosus, Systemic" ], "interventions": [ { "name": "Atacicept 75 milligram (mg)", "type": "DRUG" }, { "name": "Atacicept 150 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 306, "start_date": "2013-12", "completion_date": "2016-09", "has_results": true, "last_update_posted_date": "2018-01-02", "last_synced_at": "2026-09-05T01:36:48.498Z", "location_count": 30, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Anaheim, California + 24 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01972568" }, { "nct_id": "NCT02808429", "title": "Efficacy and Safety of Atacicept in IgA Nephropathy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "IgA Nephropathy" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Atacicept 25 mg", "type": "DRUG" }, { "name": "Atacicept 75 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2017-01-31", "completion_date": "2020-02-07", "has_results": true, "last_update_posted_date": "2021-02-25", "last_synced_at": "2026-09-05T01:36:48.498Z", "location_count": 16, "location_summary": "Glendale, Arizona • Chula Vista, California • Denver, Colorado + 13 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02808429" }, { "nct_id": "NCT00642902", "title": "A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsing Multiple Sclerosis" ], "interventions": [ { "name": "Atacicept", "type": "DRUG" }, { "name": "Placebo matched to atacicept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 255, "start_date": "2008-04", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2016-05-24", "last_synced_at": "2026-09-05T01:36:48.498Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Atlanta, Georgia • Northbrook, Illinois + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Northbrook", "state": "Illinois" }, { "city": "East Lansing", "state": "Michigan" }, { "city": "Jefferson", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00642902" }, { "nct_id": "NCT01369628", "title": "Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lupus Nephritis" ], "interventions": [ { "name": "Atacicept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2011-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-10-22", "last_synced_at": "2026-09-05T01:36:48.498Z", "location_count": 1, "location_summary": "Rockland, Massachusetts", "locations": [ { "city": "Rockland", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01369628" }, { "nct_id": "NCT00853762", "title": "Atacicept in Multiple Sclerosis Extension Study, Phase II", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsing Multiple Sclerosis" ], "interventions": [ { "name": "Atacicept 25 mg", "type": "DRUG" }, { "name": "Atacicept 75 mg", "type": "DRUG" }, { "name": "Atacicept 150 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 74, "start_date": "2009-03", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2017-03-20", "last_synced_at": "2026-09-05T01:36:48.498Z", "location_count": 6, "location_summary": "Phoenix, Arizona • Northbrook, Illinois • East Lansing, Michigan + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Northbrook", "state": "Illinois" }, { "city": "East Lansing", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00853762" }, { "nct_id": "NCT02070978", "title": "Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lupus Erythematosus, Systemic" ], "interventions": [ { "name": "Atacicept 75 mg", "type": "DRUG" }, { "name": "Atacicept 150 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 253, "start_date": "2014-07-29", "completion_date": "2018-02-09", "has_results": true, "last_update_posted_date": "2019-03-21", "last_synced_at": "2026-09-05T01:36:48.498Z", "location_count": 23, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Beverly Hills, California + 17 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fontana", "state": "California" }, { "city": "San Leandro", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02070978" } ] }